原发性胆汁性胆管炎的治疗进展

李艳梅; 王绮夏; 马雄

doi:10.3969/j.issn.1001-5256.2016.08.012

原发性胆汁性胆管炎的治疗进展

DOI: 10.3969/j.issn.1001-5256.2016.08.012

上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所

详细信息

中图分类号: R575.7
计量
- 文章访问数: 2555
- HTML全文浏览量: 28
- PDF下载量: 598
- 被引次数: 0
出版历程
- 收稿日期: 2016-04-05
- 出版日期: 2016-08-20

Research advances in treatment of primary biliary cholangitis

Department of Gastroenterology,Renji Hospital,Shanghai Jiao Tong University School of Medicine

摘要

摘要: 原发性胆汁性胆管炎是一种主要累及肝内小叶间胆管的自身免疫性肝脏疾病,可发展至肝纤维化、肝硬化甚至肝衰竭。目前熊去氧胆酸(UDCA)是唯一被批准的治疗用药,但仍有高达40%的患者对UDCA应答不佳,发生相关并发症的风险增加。目前,其他药物及治疗方法如:贝特类药物、糖皮质激素、免疫抑制剂、奥贝胆酸、生物制剂及间充质干细胞已逐步开展临床应用,为治疗此类患者带来希望。
- 肝硬化,胆汁性 /
- 熊脱氧胆酸 /
- 治疗
Abstract: Primary biliary cholangitis( PBC) is an autoimmune liver disease mainly involving intrahepatic interlobular bile ducts and can progress to liver fibrosis,cirrhosis,and even liver failure. At present,the only drug approved for the treatment of PBC is ursodeoxycholic acid( UDCA),but up to 40% of PBC patients have suboptimal response to UDCA,and the risk of related complications is increased. Nowadays,other drugs and treatment methods,such as fibrates,glucocorticoids,immunosuppressants,obeticholic acid,biological agents,and mesenchymal stem cells,have been gradually applied in clinical practice and have brought the hope for the treatment of these patients.
- liver cirrhosis /
- biliary /
- ursodeoxycholic acid

HTML全文

参考文献(53)

[1]BOONSTRA K,BEUERS U,PONSIOEN CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review[J].J Hepatol,2012,56(5):1181-1188.

[2]CAREY EJ,ALI AH,LINDOR KD.Primary biliary cirrhosis[J].Lancet,2015,386(10003):1565-1575.

[3]MAYO MJ.Natural history of primary biliary cirrhosis[J].Clin Liver Dis,2008,12(2):277-288.

[4]PRINCE M,CHETWYND A,NEWMAN W,et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology,2002,123(4):1044-1051.

[5]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J].临床肝胆病杂志,2015,31(12):1980-1988.

[6]INVERNIZZI P,PODDA M,BATTEZZATI PM,et al.Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis[J].J Hepatol,2001,34(3):366-372.

[7]NAKAMURA M,KONDO H,MORI T,et al.Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology,2007,45(1):118-127.

[8]LUDWIG J,DICKSON ER,McD ONALD GS.Staging of chronic nonsuppurative destructive cholangitis(syndrome of primary biliary cirrhosis)[J].Virchows Arch A Pathol Anat Histol,1978,379(2):103-112.

[9]YOU Z,WANG Q,BIAN Z,et al.The immunopathology of liver granulomas in primary biliary cirrhosis[J].J Autoimmun,2012,39(3):216-221.

[10]POUPON RE,LINDOR KD,CAUCHDUDEK K,et al.Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis[J].Gastroenterology,1997,113(3):884-890.

[11]ANGULO P,BATTS KP,THERNEAU TM,et al.Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis[J].Hepatology,1999,29(3):644-647.

[12]IMAM MH,LINDOR KD.The natural history of primary biliary cirrhosis[J].Semin Liver Dis,2014,34(3):329-333.

[13]POUPON RE,BONNAND AM,CHRETIEN Y,et al.Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis[J].Hepatology,1999,29(6):1668-1671.

[14]ALI AH,CAREY EJ,LINDOR KD.The management of autoimmunity in patients with cholestatic liver diseases[J].Expert Rev Gastroenterol Hepatol,2016,10(1):73-91.

[15]PARES A,CABALLERIA L,RODES J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J].Gastroenterology,2006,130(3):715-720.

[16]TRIVEDI PJ,LAMMERS WJ,van BUUREN HR,et al.Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis:a multicentre international study[J].Gut,2016,65(2):321-329.

[17]CORPECHOT C,ABENAVOLI L,RABAHI N,et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology,2008,48(3):871-877.

[18]LAMMERS WJ,HIRSCHFIELD GM,CORPECHOT C,et al.Development and validation of a scoring system to predict outcomes o patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology,2015,149(7):1804-1812.

[19]NAKAI S,MASAKI T,KUROKOHCHI K,et al.Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis:a preliminary study[J].Am J Gastroenterol,2000,95(1):326-327.

[20]KURIHARA T,NIIMI A,MAEDA A,et al.Bezafibrate in the treatment of primary biliary cirrhosis:comparison with ursodeoxycholic acid[J].Am J Gastroenterol,2000,95(10):2990-2992.

[21]HAN XF,WANG QX,LIU Y,et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis,2012,13(4):219-224.

[22]ZHANG Y,LI S,HE L,et al.Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis[J].Drug Des Devel Ther,2015,9:2757-2766.

[23]YIN Q,LI J,XIA Y,et al.Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhosis[J].Drug Des Devel T-her,2015,9:5407-5419.

[24]LEUSCHNER M,MAIER KP,SCHLICHTING J,et al.Ora budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis:results of a prospective double-blind trial[J].Gastroenterology,1999,117(4):918-925.

[25]ANGULO P,JORGENSEN RA,KEACH JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptima response to ursodeoxycholic acid[J].Hepatology,2000,31(2):318-323.

[26]RAUTIAINEN H,KARKKAINEN P,KARVONEN AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology,2005,41(4):747-752.

[27]RAUTIAINEN H,FARKKILA M,NEUVONEN M,et al.Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis[J].Aliment Pharmacol Ther,2006,24(11-12):1545-1552.

[28]HEMPFLING W,DILGER K,REICHEL C,et al.Pharmacokinetics and pharmacodynamic action of budesonide in early-and latestage primary biliary cirrhosis[J].Hepatology,2003,38(1):196-202.

[29]FANG YQ,LV DX,JIA W,et al.Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases efficacy and safety analysis[J].Medicine,2014,93(20):e104.

[30]RABAHI N,CHRETIEN Y,GAOUAR F,et al.Triple therapy with ursodeoxycholic acid,budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J].Gastroenterol Clin Biol,2010,34(4-5):283-287.

[31]POUPON R.Evidence-based treatment of primary biliary cirrhosis[J].Dig Dis,2014,32(5):626-630.

[32]COMBES B,EMERSON SS,FLYE NL,et al.Methotrexate(MTX)plus ursodeoxycholic acid(UDCA)in the treatment of primary biliary cirrhosis[J].Hepatology,2005,42(5):1184-1193.

[33]KAPLAN MM,BONDER A,RUTHAZER R,et al.Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J]Dig Dis Sci,2010,55(11):3207-3217.

[34]GILJACA V,POROPAT G,STIMAC D,et al.Methotrexate for primary biliary cirrhosis[J].Cochrane Database Syst Rev,2010,(5):CD004385.

[35]LOMBARD M,PORTMANN B,NEUBERGER J,et al.Cyclosporin A treatment in primary biliary cirrhosis:results of a long-term placebo controlled trial[J].Gastroenterology,1993,104(2):519-526.

[36]SHIBA H,WAKIYAMA S,FUTAGAWA Y,et al.Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation[J].Int Surg,2013,98(2):156-159.

[37]PELLICCIARI R,FIORUCCI S,CAMAIONI E,et al.6 alphaethyl-chenodeoxycholic acid(6-ECDCA),a potent and selective FXR agonist endowed with anticholestatic activity[J].J Med Chem,2002,45(17):3569-3572.

[38]FIORUCCI S,RIZZO G,DONINI A,et al.Targeting farnesoid Xreceptor for liver and metabolic disorders[J].Trends Mol Med,2007,13(7):298-309.

[39]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.e8.

[40]KOWDLEY KV,JONES D,LUKETIC V,et al.An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC[J].J Hepatol,2011,54(9):s13.

[41]NEVENS F,ANDREONE P,MAZZELLA G,et al.The first primary biliary cirrhosis(PBC)phase 3 trial in two decades-an international study of the fxr agonist obeticholic acid in PBC patients[J].J Hepatol,2014,60(1):s525-s526.

[42]AVIVI I,STROOPINSKY D,KATZ T.Anti-CD20 monoclonal antibodies:beyond B-cells[J].Blood Rev,2013,27(5):217-223.

[43]MORITOKI Y,LIAN ZX,LINDOR K,et al.B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice[J].Hepatology,2009,50(6):1893-1903.

[44]TSUDA M,MORITOKI Y,LIAN ZX,et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology,2012,55(2):512-521.

[45]MYERS RP,SWAIN MG,LEE SS,et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol,2013,108(6):933-941.

[46]TAJIRI K,TSUNEYAMA K,MIYAZONO T,et al.A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab[J].Case Rep Gastroenterol,2013,7(1):195-201.

[47]JOPSON L,NEWTON JL,PALMER J,et al.RITPBC:B-cell depleting therapy(rituximab)as a treatment for fatigue in primary biliary cirrhosis:study protocol for a randomised controlled trial[J].BMJ Open,2015,5(8):e007985.

[48]MELLS GF,FLOYD JAB,MORLEY KI,et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet,2011,43(4):329-332.

[49]YOSHIDA K,YANG GX,ZHANG W,et al.Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice[J].Hepatology,2009,50(5):1494-1500.

[50]HIRSCHFIELD GM,GERSHWIN ME,STRAUSS R,et al.Phase 2study evaluating the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid[J].J Hepatol,2014,60(1):s189-s190.

[51]DHIRAPONG A,YANG GX,NADLER S,et al.Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis[J].Hepatology,2013,57(2):708-715.

[52]MOUSA HS,LLEO A,INVERNIZZI P,et al.Advances in pharmacotherapy for primary biliary cirrhosis[J].Expert Opin Pharmacother,2015,16(5):633-643.

[53]WANG L,HAN Q,CHEN H,et al.Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J].Stem Cells Dev,2014,23(20):2482-2489.

施引文献

资源附件(0)

访问统计